Technical / white paper
Id Counterfeit Pharmaceuticals with Portable Raman
Rigaku
Shasun’s Pharma more than doubled its net profits in Q1 thanks to its thriving API (active pharmaceutical ingredient) contract manufacturing business.
The results follow a $19m (RS 105.5m) investment in a new API facility in Vizag, India, which the firm expects will fetch $100m return over the next three years.
The first quarter has so far seen earnings of $2.5m, compared to $12.3m last year.
“There has been an overall growth in the CRAMS (contract research and manufacturing services) business. This constitutes over 50 per cent of our consolidated business,” CFO S Hariharan told The Hindu Business Line.
Of the future, the firm says growth investments will be geared towards new API products.
